Compositions and methods for targeted delivery to cells
US-2024390271-A1 · Nov 28, 2024 · US
US2017333344A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017333344-A1 |
| Application number | US-201715495199-A |
| Country | US |
| Kind code | A1 |
| Filing date | Apr 24, 2017 |
| Priority date | Feb 11, 2010 |
| Publication date | Nov 23, 2017 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.
Opening claim text (preview).
1 . Method for reducing the percentage of aggregate formation in atomized material of immunoglobulin single variable domains comprising atomizing in a vibrating-mesh nebulizer a composition comprising an aqueous carrier and a polypeptide comprising one or more immunoglobulin single variable domains, wherein: the concentration of the polypeptide comprising one or more immunoglobulin single variable domains present in the composition is 50 mg/mL or more, wherein the aqueous carrier comprises saline (NaCl 0.9%), histidine, and phosphate buffered saline; and the percentage of aggregate formation in the atomized material, as determined by SE-HPLC, is reduced compared to the percentage of aggregate formation in atomized material obtained from a composition of immunoglobulin single variable domains at a concentration of 5 mg/mL or atomized in a jet nebulizer. 2 . Method of claim 1 , wherein the composition further comprises a surfactant at a concentration between 0.001% and 1%. 3 . Method of claim 2 , wherein the surfactant is selected from polysorbates and poloxamers, or wherein PEG is added as a surfactant-like compound. 4 . (canceled) 5 . (canceled) 6 . Method of claim 1 , wherein the polypeptide comprising one or more immunoglobulin single variable domains is present at a concentration of 50 mg/mL to 200 mg/mL and wherein the composition does not comprise a surfactant. 7 .- 38 . (canceled)
for RNA viruses · CPC title
Drugs for disorders of the respiratory system · CPC title
Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title
for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions · CPC title
Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.